Clinical application of biological markers for treatments of resectable non-small-cell lung cancers

C Huang*,1, D Liu1, D Masuya1, T Nakashima1, K Kameyama1, S Ishikawa1, M Ueno2, R Haba3 and H Yokomise1
1Second Department Surgery, Faculty of Medicine, Kagawa University, 1750-1, Miki-cho, Kita-gun, Kagawa 761-0793, Japan; 2Pathology and Host Defense, Faculty of Medicine, Kagawa University, Kagawa, Japan; 3Department of Pathology, Faculty of Medicine, Kagawa University, Kagawa, Japan

We performed a clinical study to identify biological markers useful for the treatment of resectable non-small-cell lung cancers (NSCLCs). In all, 173 patients were studied. By immunohistochemistry, we evaluated the Ki-67 proliferation index, tumour vascularity, thymidylate synthase (TS), vascular endothelial growth factor (VEGF)-A, VEGF-C, and E (epithelial)-cadherin. Concerning the survival of NSCLC patients, tumour vascularity (P<0.01), VEGF-A status (P=0.03), VEGF-C status (P=0.03), and E-cadherin status (P=0.03) were significant prognostic factors in patients with stage I NSCLCs. The Ki-67 proliferation index (P=0.02) and TS status (P<0.01) were significant prognostic factors in patients with stage II–III NSCLCs. In patients with stage II–III NSCLCs, furthermore, the survival of UFT (a combination of tegafur and uracil)-treated patients with TS-negative tumours was significantly better than those of any other patients. Biological markers associated with tumour angiogenesis or metastasis are useful for the detection of aggressive tumours among early-stage NSCLCs. Postoperative chemotherapy might be necessary in such tumours even in stage I. In contrast, tumour proliferation rate and TS status are useful markers for identifying less aggressive tumours in locally advanced NSCLCs. Thymidylate synthase expression is also a useful marker to evaluate responsiveness of UFT-based chemotherapy for these tumours.

British Journal of Cancer (2005) 92, 1231 – 1239. doi:10.1038/sj.bjc.6602481 www.bjcancer.com
Published online 22 March 2005
© 2005 Cancer Research UK

Keywords: lung cancer; biological marker; prognosis; immunohistochemistry

Non-small-cell lung cancer (NSCLC) is one of the most common human malignancies with a poor prognosis. Surgical resections play major roles in managing patients with stage I and stage II NSCLCs, and may be used for patients with stage III NSCLCs (Cersosimo, 2002). In addition, various combined-modality therapy, including chemotherapy and radiation therapy, have been assessed for improving the outcome of patients with NSCLCs (Arriagada et al, 2004; Machtay et al, 2004; Strauss et al, 2004; Winton et al, 2004). However, the 3-year survival of stage II NSCLC patients was 35–55%, and the 3-year survival of resectable stage III NSCLC patients was 28% (Martin et al, 2002). Therefore, a new therapeutic strategy is required for patients with resectable NSCLCs.

Owing to developments in molecular biology, many clinical studies on molecular markers associated with tumour biological behaviour have been performed in human cancers, and these molecular markers, including oncogenes, tumour suppressor genes (Huang et al, 1998), metastatic suppressor genes (Adachi et al, 1998; Sulzer et al, 1998), and angiogenic factors (Imoto et al, 1998; Masuya et al, 2001), could be prognostic factors for NSCLC patients. Therefore, to improve the treatment of NSCLC patients, it is important to decide the optimal therapeutic strategy for them according to the tumour biology. Our previous studies demonstrated four biological markers, including thymidylate synthase (TS) (Huang et al, 2000), vascular endothelial growth factor-A (VEGF-A), VEGF-C (Nakashima et al, 2004), and E (epithelial)-cadherin (Liu et al, 2001), to be significant prognostic factors for NSCLC patients. Thymidylate synthase is reported to be related to tumour cell proliferation and responsiveness to 5-FU-based chemotherapy (Navalgund et al, 1980; Beck et al, 1994). VEGF-A and VEGF-C are members of the VEGF family associated with angiogenesis or lymphangiogenesis (Dvorak et al, 1995; Skobe et al, 2001). E-cadherin is one of the metastatic suppressor genes (Mbalaviele et al, 1996; Sulzer et al, 1998).

Therefore, we performed a retrospective clinical study to identify molecular markers useful for the treatment of patients with resectable NSCLCs. We evaluated the intratumoral expressions of these four biological markers: TS, VEGF-A, VEGF-C, and E-cadherin. In addition, we studied the tumour proliferation rate using the Ki-67 index (Gerdes et al, 1984; Scagliotti et al, 1993) and tumour angiogenesis using CD34 staining (Matsuyama et al, 1998).

MATERIALS AND METHODS

Clinical characteristics of patients

From January 1995 to December 1997, consecutive NSCLC patients who underwent surgery at the Second Department of Surgery, Faculty of Medicine, Kagawa University were studied. This study was approved by the institutional review board of Kagawa University (14-7, a clinical study of biological markers in NSCLCs). TNM staging designations were made according to the postsurgical pathological international staging system (Mountain, 1997). In total, 173 patients with lung cancer up to stage III were

*Correspondence: Dr C Huang; E-mail: chuang@kms.ac.jp
Received 16 August 2004; revised 20 January 2005; accepted 31 January 2005; published online 22 March 2005
investigated (Table 1). These included 97 patients with stage I NSCLCs, 17 patients with stage II NSCLCs, and 59 patients with stage III NSCLCs. Patients’ clinical records and histopathological diagnoses were fully documented. This report includes follow-up data as of 31 March 2004. The median follow-up period for all patients was 77.0 ± 28.9 months.

Regarding methods of surgical resection, a pneumonectomy was performed in 16 patients with stage II–III NSCLCs. A lobectomy was performed in 133 patients: 73 patients with stage I NSCLCs, 15 patients with stage II NSCLCs, and 45 patients with stage III NSCLCs. A segmentectomy was performed in three patients with stage I NSCLCs, and a wedge resection was performed in 21 patients with stage I NSCLCs. Systemic chemotherapy using mitomycin/vinblastin/cisplatin (MVP) was performed in all patients with stage II–III NSCLCs; neoadjuvant chemotherapy in 49 patients, and postoperative adjuvant chemotherapy in 27 patients with nodal metastases. Radiation therapy was performed in 18 patients: 11 patients with T3 or T4 status and seven patients with mediastinal lymph node metastases. 5-FU was administered as UFT (a combination of tegafur and uracil, Taiho Pharmaceutical Co., Tokyo, Japan; 300–400 mg day⁻¹ body⁻¹) to 107 patients including 53 patients with stage I NSCLCs and 54 patients with stage II–III NSCLCs. Oral administration of UFT was started within 1 month after surgery. UFT was administered for 2 years if there was no recurrence of carcinomas. In patients with recurrences, UFT was given until its oral administration became impossible.

**Immunohistochemistry**

The following antibodies were used, along with isotype antibodies as negative controls: a mouse monoclonal antibody for the Ki-67 antigen (MIB-1, DAKO, Glostrup, Denmark) diluted at 1:40, a mouse monoclonal antibody for CD34 (NU-4A1, Nichirei Corporation, Tokyo, Japan) diluted at 1:10, a rabbit polyclonal antibody for TS (kindly provided by Dr M Fukushima) (Huang et al., 2000) diluted at 1:500, a rabbit polyclonal antibody for VEGF-A (A-20, Santa Cruz Biotechnology, Santa Cruz, CA, USA) diluted at 1:200, a goat polyclonal antibody for VEGF-C (N-19, Santa Cruz Biotechnology) diluted at 1:100, and a mouse monoclonal antibody for E-cadherin (HECD-1, Takara, Otsu, Japan) diluted at 1:400.

Formalin-fixed paraffin-embedded tissue was cut into 4-μm sections and mounted onto poly-l-lysine-coated slides. Sections were deparaffinised and rehydrated. The slides were then heated in a microwave for 10 min in a 10-μmol L⁻¹ citrate buffer solution at pH 6.0, and cooled to room temperature for 20 min. After quenching the endogenous peroxidase activity with 0.3% H₂O₂ in absolute methanol for 30 min, the sections were treated for 2 h at room temperature with 5% bovine serum albumin to block nonspecific staining. Duplicate sections were incubated overnight with the primary specific antibodies detecting Ki-67, CD34, TS, VEGF-A, VEGF-C, and E-cadherin. Slides were then incubated for 1 h with biotinylated anti-mouse IgG (Vector Laboratories Inc., Burlingame, CA, USA) for Ki-67, CD34, and E-cadherin. Avidin-biotin peroxidase complex (Vector Laboratories Inc.) for TS and VEGF-A, and biotinylated anti-goat IgG (Vector Laboratories Inc.) for VEGF-C. The sections were incubated with the avidin–biotin–peroxidase complex (Vector Laboratories Inc.) for 1 h, and antibody binding was visualised with 3,3′-diaminobenzidine tetrahydrochloride. Lastly, the sections were lightly counterstained with Mayer’s haematoxylin. The human colon cancer cell line DLD-1/Furud was used as a positive control for the staining of TS.

**Assessment of immunohistochemical staining**

All of the immunostained sections were reviewed by two pathologists (M Ueno and R Haba) who had no knowledge of the patients’ clinical status. The percentage of carcinoma cells with positive staining for Ki-67 in a given specimen was scored as the Ki-67 proliferation index, and tumours with ≥25% of Ki-67 proliferation index were classified as high Ki-67 (Scaglioni et al., 1993). For microvessel quantification, the three most highly vascularised areas detected by CD34 immunostaining were initially selected under the ×40 field, and a ×200 field (0.785 mm² per field) was used to count vessels in each of these areas. The average of three ×200 field counts was recorded as the intratumoral microvessel density (IMD). Tumours with ≥90 of the IMD were classified as hypervascular (Masuya et al., 2001).

For TS, VEGF-A VEGF-C, and E-cadherin, samples were classified into two groups, positive or negative, with a cutoff value based on the findings of previous reports, respectively. At least 200 tumour cells were scored per ×40 field. All sections were scored in a semiquantitative manner according to the method described previously, which reflects both the intensity and percentage of cells staining at each intensity (McCarty et al., 1986). Intensity was
classified as 0 (no staining), + 1 (weak staining), + 2 (distinct staining), or + 3 (very strong staining). A value designated the 'HSCORE' was obtained for each slide by using the following algorithm: HSCORE = \( \Sigma (I \times PC) \), where I and PC represent staining intensity and the percentage of cells that stain at each intensity, respectively, and the corresponding HSCOREs were calculated separately. Concerning TS expression, when the HSCORE of TS in a given specimen was \( \geq 30 \), the sample was classified as TS-positive (Huang et al., 2000). Expressions of VEGF-A, VEGF-C, and E-cadherin were classified as follows: when \( \geq 30\% \) of the carcinoma cells in a given specimen were positively stained for VEGF-A, the sample was classified as VEGF-A-positive (Masuya et al., 2001); when \( \geq 30\% \) of the carcinoma cells in a given specimen were positively stained for VEGF-C, the sample was classified as VEGF-C-positive (Arinaga et al., 2003); and when \( \geq 50\% \) of the carcinoma cells in a given specimen were positively stained for E-cadherin, the sample was classified as E-cadherin-positive (Liu et al., 2001).

**Statistical analysis**

The statistical differences in the expression of each biological marker in relation to various clinical and pathological parameters were assessed by the \( \chi^2 \) test. Overall survival was defined as the time from treatment initiation (surgical resection, chemotherapy, or radiation) to the date of death from any cause. The Kaplan–Meier method was used to estimate the probability of overall survival as a function of time, and differences in the survival of subgroups of patients were compared by using Mantel’s log-rank test. Multivariate analyses were performed using the Cox regression model to study the effects on survival (Cox, 1972). The \( P \)-values were based on two-tailed statistical analysis, and a \( P \)-value < 0.05 was considered to indicate statistically significance.

### Table 2: Distribution of biological markers in 173 NSCLC patients according to clinicopathological characteristics

| Characteristics          | High Ki-67 | Hypervascular | TS-positive | VEGF-A-positive | VEGF-C-positive | E-cadherin-negative |
|--------------------------|------------|---------------|-------------|-----------------|-----------------|---------------------|
|                          | n (%)      | P-value (%)   | P-value (%) | P-value (%)     | P-value (%)     | P-value (%)         |
| **Smoking**              |            |               |             |                 |                 |                     |
| Nonsmoker                | 65 50.8    | <0.01         | 61.5        | 0.15            | 53.8            | 0.98                | 49.2                | 0.49                | 38.5                | 0.44                | 55.4                | 0.79                | 57.4                | 0.74                |
| Smoker                   | 108 77.8   |               | 49.1        | 53.7            | 54.6            | 44.4               |                     |                     |                     |                     |                     |                     |                     |                     |
| **Tumour status**        |            |               |             |                 |                 |                     |                     |                     |                     |                     |                     |                     |                     |                     |
| T1, T2                   | 125 68.8   | 0.59          | 52.0        | 0.45            | 50.4            | 0.15               | 51.2                | 0.55                | 41.6                | 0.79                | 53.6                | 0.19                | 64.6                | 0.19                |
| T3, T4                   | 48 64.6    |               | 58.3        | 62.5            | 36.3            | 43.8               |                     |                     |                     |                     |                     |                     |                     |                     |
| **Nodal status**         |            |               |             |                 |                 |                     |                     |                     |                     |                     |                     |                     |                     |                     |
| N0                       | 120 65.0   | 0.26          | 53.3        | 0.86            | 51.7            | 0.40               | 47.5                | 0.04                | 42.5                | 0.90                | 50.8                | 0.02                | 69.8                | 0.02                |
| N1, N2                   | 53 73.6    |               | 54.7        | 58.5            | 64.2            | 41.5               |                     |                     |                     |                     |                     |                     |                     |                     |
| **Pathological status**  |            |               |             |                 |                 |                     |                     |                     |                     |                     |                     |                     |                     |                     |
| Stage I                  | 97 69.1    | 0.39          | 51.5        | 0.54            | 52.6            | 0.39               | 48.5                | 0.21                | 40.2                | 0.78                | 50.5                | 0.09                | 76.5                | 0.09                |
| Stage II                 | 17 52.9    |               | 47.1        | 41.2            | 29.4            | 41.2               |                     |                     |                     |                     |                     |                     |                     |                     |
| Stage III                | 59 69.5    |               | 59.3        | 59.3            | 66.1            | 45.8               |                     |                     |                     |                     |                     |                     |                     |                     |
| **Histology**            |            |               |             |                 |                 |                     |                     |                     |                     |                     |                     |                     |                     |                     |
| Adenocarcinoma           | 101 56.4   | <0.01         | 65.3        | <0.01           | 43.6            | <0.01              | 54.5                | 0.70                | 45.5                | 0.22                | 52.5                | 0.06                | 56.9                | 0.06                |
| Squamous cell carcinoma  | 58 87.9    |               | 32.8        | 72.4            | 51.7            | 41.4               |                     |                     |                     |                     |                     |                     |                     |                     |
| Large cell carcinoma     | 14 64.3    |               | 57.1        | 50.0            | 42.9            | 21.4               |                     |                     |                     |                     |                     |                     |                     |                     |
| **Neoadjuvant MVP**      |            |               |             |                 |                 |                     |                     |                     |                     |                     |                     |                     |                     |                     |
| Without neoadjuvant MVP  | 124 70.9   | 0.19          | 52.4        | 0.69            | 53.2            | 0.95               | 52.4                | 0.93                | 43.5                | 0.68                | 54.0                | 0.35                | 63.3                | 0.35                |
| With neoadjuvant MVP     | 49 59.2    |               | 57.1        | 55.1            | 53.1            | 36.8               |                     |                     |                     |                     |                     |                     |                     |                     |
| **Total number of patients** | 173 67.6   |               | 53.8        | 53.8            | 52.6            | 42.2               |                     |                     |                     |                     |                     |                     |                     |                     |

NSCLC = non-small-cell lung cancer; TS = thymidylate synthase; VEGF = vascular endothelial growth factor; MVP = mitomycin/vinblastin/cisplatin.

### RESULTS

**Distribution of biological markers in NSCLCs**

Concerning the Ki-67 proliferation index, 117 carcinomas (67.6%) had high Ki-67 (Table 2). The frequency of high Ki-67 tumours was significantly higher in squamous cell carcinomas than in adenocarcinomas (87.9 vs 56.4%, \( P < 0.01 \)). However, there was no difference in the Ki-67 index in relation to tumour status, nodal status, pathological stage, or neoadjuvant chemotherapy.

With respect to tumour angiogenesis, 93 carcinomas (53.8%) were hypervascular tumours. The frequency of hypervascular tumours was significantly higher in adenocarcinomas than in squamous cell carcinomas (65.3 vs 32.8%, \( P < 0.01 \)). There was no difference in the IMD according to tumour status, nodal status, pathological stage, or neoadjuvant chemotherapy.

Concerning the intratumoral TS expression status, 93 carcinomas (53.8%) were TS-positive. The frequency of TS-positive tumours was significantly higher in squamous cell carcinomas than in adenocarcinomas (72.4 vs 43.6%, \( P < 0.01 \)). There was also no difference in TS status according to tumour status, nodal status, pathological stage, or neoadjuvant chemotherapy.

In all, 91 carcinomas (52.6%) were VEGF-A-positive tumours. There was no difference in VEGF-A status in relation to tumour histology or neoadjuvant chemotherapy. However, the frequency of nodal metastases was significantly higher in VEGF-A-positive tumours than in VEGF-A-negative tumours (37.4 vs 23.2%, \( P < 0.04 \)).

A total of 73 carcinomas (42.2%) were VEGF-C-positive tumours. There was no difference in VEGF-C status in relation to tumour histology, tumour status, nodal status, pathological stage, or neoadjuvant chemotherapy.

In total, 98 carcinomas (56.6%) were E-cadherin-negative. There was no difference in E-cadherin status in relation to tumour histology or neoadjuvant chemotherapy. However, the frequency...
of nodal metastases was significantly higher in E-cadherin-negative tumours than in E-cadherin-positive tumours (37.8 vs 21.3%, \( P = 0.02 \)).

**Ki-67 proliferation index in relation to biological markers in NSCLCs**

Concerning TS status, the Ki-67 proliferation index was significantly higher in TS-positive tumours than in TS-negative tumours (48.6 ± 29.9 vs 35.6 ± 29.8, \( P < 0.01 \)). Regarding VEGF-A status, the Ki-67 proliferation index was significantly higher in VEGF-A-positive tumours than in VEGF-A-negative tumours (46.9 ± 31.5 vs 37.7 ± 28.6, \( P = 0.04 \)). However, there was no difference in the Ki-67 proliferation index in relation to VEGF-C or E-cadherin status.

**IMD in relation to biological markers in NSCLCs**

Concerning VEGF-A status, the IMD was significantly higher in VEGF-A-positive tumours than in VEGF-A-negative tumours (118.9 ± 51.6 vs 91.1 ± 55.8, \( P < 0.01 \)). However, there was no difference in the IMD in relation to TS, VEGF-C, or E-cadherin status.

**Survival of patients with stage I NSCLCs in relation to biological markers**

The 5-year survival rates of 97 patients with stage I NSCLCs in relation to biological markers are shown in Table 3. With respect to patients with stage I NSCLCs, there was no significant difference in the 5-year survival rates between patients with high Ki-67 tumours and those with low Ki-67 tumours (70.0 vs 82.2%, Figure 1A). In contrast, the 5-year survival rate of patients with hypervascular tumours was significantly lower than that of patients with hypovascular tumours (58.3 vs 83.5%, \( P < 0.01 \), Figure 1B).

On the other hand, there was no significant difference in the 5-year survival rates between patients with TS-positive tumours and those with TS-negative tumours (60.7 vs 81.8%, Figure 1C).

Regarding the TS status and UFT-based chemotherapy, there was no significant difference in the 5-year survival rates according to intratumoral TS status and UFT-based chemotherapy among stage I NSCLCs (Figure 1D). There was also no significant difference in the 5-year survival rates according to intratumoral TS status and UFT-based chemotherapy among stage I adenocarcinomas of the lung (72.2% in UFT-treated patients with TS-negative tumours, 77.2% in UFT-untreated patients with TS-negative tumours, 56.3% in UFT-treated patients with TS-positive tumours, and 66.7% in UFT-untreated patients with TS-positive tumours).

In contrast, the 5-year survival rate of patients with VEGF-A-positive tumours was significantly lower than that of patients with VEGF-A-negative tumours (58.6 vs 82.2%, \( P = 0.01 \), Figure 1E). The 5-year survival rate of patients with VEGF-C-positive tumours was also significantly lower than that of patients with VEGF-C-negative tumours (54.9 vs 80.3%, \( P < 0.01 \), Figure 1F). Furthermore, the 5-year survival rate of patients with E-cadherin-negative tumours was significantly lower than that of patients with E-cadherin-positive tumours (55.2 vs 85.3%, \( P = 0.01 \), Figure 1G).

The multivariate analysis demonstrated that four variables, IMD (hazard ratio = 3.34, \( P < 0.01 \)), VEGF-A status (hazard ratio = 2.37, \( P = 0.03 \)), VEGF-C status (hazard ratio = 2.10, \( P = 0.03 \)), and E-cadherin status (hazard ratio = 2.30, \( P = 0.03 \)), were significant prognostic factors in patients with stage I NSCLCs (Table 4). The proportional hazards assumption was met adequately.

**Survival of patients with stage II – III NSCLCs in relation to biological markers**

The 5-year survival rates of 76 patients with stage II – III NSCLCs in relation to biological markers are also shown in Table 3. With respect to patients with stage II – III (locally advanced) NSCLCs, the 5-year survival rate of patients with low Ki-67 tumours was significantly higher than that of patients with high Ki-67 tumours (43.2 vs 20.0%, \( P = 0.02 \), Figure 2A). Especially, the 5-year survival rate of patients with low Ki-67 tumours was significantly higher than that of patients with high Ki-67 tumours among stage III (42.8

### Table 3 The 5-year survival rate of 173 NSCLC patients in relation to biological markers and pathological stage

| Characteristics     | Stage I (%) | P-value | Stage II (%) | P-value | Stage III (%) | P-value | Stage II–III (%) | P-value | Total (%) | P-value |
|---------------------|-------------|---------|--------------|---------|---------------|---------|------------------|---------|-----------|---------|
| Ki-67 index         |             |         |              |         |               |         |                  |         |           |         |
| Low                 | 82.2        | 0.57    | 43.8         | 0.45    | 42.8          | 0.04    | 43.2             | 0.02    | 67.0      | 0.01    |
| High                | 70.0        |         | 33.3         |         | 16.7          |         | 20.0             |         | 44.1      |         |
| IMD                 |             |         |              |         |               |         |                  |         |           |         |
| Hypovascular        | 83.5        | <0.01   | 50.8         | 0.30    | 25.7          | 0.60    | 31.1             | 0.82    | 62.3      | 0.02    |
| Hypervascular       | 58.3        |         | 25.0         |         | 23.6          |         | 24.6             |         | 43.1      |         |
| TS status           |             |         |              |         |               |         |                  |         |           |         |
| Negative            | 81.8        | 0.26    | 45.0         | 0.23    | 45.9          | <0.01   | 45.8             | <0.01   | 66.3      | <0.01   |
| Positive            | 60.7        |         | 28.6         |         | 8.7           |         | 12.6             |         | 39.2      |         |
| VEGF-A status       |             |         |              |         |               |         |                  |         |           |         |
| Negative            | 82.2        | 0.01    | 55.6         | 0.20    | 35.0          | 0.75    | 42.6             | 0.37    | 66.5      | <0.01   |
| Positive            | 58.6        |         | 0.0          |         | 19.3          |         | 16.9             |         | 38.7      |         |
| VEGF-C status       |             |         |              |         |               |         |                  |         |           |         |
| Negative            | 80.3        | <0.01   | 40.0         | 0.91    | 27.5          | 0.75    | 30.3             | 0.88    | 59.2      | 0.03    |
| Positive            | 54.9        |         | 34.3         |         | 21.6          |         | 24.3             |         | 40.6      |         |
| E-cadherin status   |             |         |              |         |               |         |                  |         |           |         |
| Positive            | 85.3        | 0.01    | 50.0         | 0.93    | 32.6          | 0.15    | 35.6             | 0.28    | 67.5      | <0.01   |
| Negative            | 55.2        |         | 33.8         |         | 18.6          |         | 22.6             |         | 38.9      |         |

NSCLC = non-small-cell lung cancer; IMD = intratumoral microvessel density; TS = thymidylate synthase; VEGF = vascular endothelial growth factor; MVP = mitomycin/vinblastin/cisplatin; E-cadherin = epithelial cadherin.
However, there was no difference in the 5-year survival rates between patients with hypovascular tumours and those with hypervascular tumours (31.1% vs 24.6%, Figure 2B).

Concerning TS status, the 5-year survival rate of patients with TS-negative tumours was significantly higher than that of patients with TS-positive tumours among stage II–III (45.8% vs 12.6%,

Figure 1  Overall survival of patients with stage I NSCLCs in relation to biological markers. (A) Ki-67 index, (B) tumour vascularity, (C) TS status, (D) TS status and UFT-based chemotherapy, (E) VEGF-A status, (F) VEGF-C status, and (G) E-cadherin status.

vs 16.7%, $P = 0.04$). However, there was no difference in the 5-year survival rates between patients with hypovascular tumours and those with hypervascular tumours (31.1% vs 24.6%, Figure 2B).

Concerning TS status, the 5-year survival rate of patients with TS-negative tumours was significantly higher than that of patients with TS-positive tumours among stage II–III (45.8% vs 12.6%,
Table 4 Multivariate regression analyses in predicting survival of NSCLC patients

| Biological markers | Stage I | | | Stage II, III |
|--------------------|--------|--------|--------|--------|
|                    | Hazard ratio | 95% CI | P-value | Hazard ratio | 95% CI | P-value |
| Ki-67 index        | 1.75    | 0.73–4.21 | 0.20   | 2.04    | 1.09–3.80 | 0.02   |
| IMD                | 3.34    | 1.30–7.86 | <0.01  | 1.38    | 0.75–2.54 | 0.28   |
| TS status          | 1.31    | 0.57–2.98 | 0.51   | 2.43    | 1.34–4.42 | <0.01  |
| VEGF-A status      | 2.37    | 1.07–5.24 | 0.03   | 1.27    | 0.69–2.35 | 0.43   |
| VEGF-C status      | 2.10    | 1.04–4.37 | 0.03   | 0.94    | 0.54–1.64 | 0.83   |
| E-cadherin status  | 2.30    | 1.03–5.16 | 0.03   | 1.50    | 0.85–2.63 | 0.15   |

NSCLC = non-small-cell lung cancer; CI = confidence interval; IMD = intratumoral microvessel density; TS = thymidylate synthase; VEGF = vascular endothelial growth factor; MVP = mitomycin/vinblastin/cisplatin; E-cadherin = epithelial cadherin.

$P < 0.01$, Figure 2C). Especially, the 5-year survival rate of patients with TS-negative tumours was significantly higher than that of patients with TS-positive tumours among stage III (45.9 vs 8.7%, $P < 0.01$). Regarding TS status and UFT-based chemotherapy, furthermore, the 5-year survival rates were 53.8% in UFT-treated patients with TS-negative tumours, 15.0% in UFT-untreated patients with TS-negative tumours, 15.2% in UFT-treated patients with TS-positive tumours, and 7.1% in UFT-untreated patients with TS-positive tumours (Figure 2D). In patients with stage II–III NSCLCs, the 5-year survival rate of UFT-treated patients with TS-negative tumours was significantly higher than that of any other patients ($P = 0.04$, $P < 0.01$, and $P < 0.01$, respectively).

However, there was no difference in the survival of patients with stage II–III NSCLCs in relation to intratumoral expressions of VEGF-A, VEGF-C, or E-cadherin (Figure 2E–G).

The multivariate analysis also demonstrated that the Ki-67 proliferation index (hazard ratio = 2.04, $P = 0.02$) and TS status (hazard ratio = 2.43, $P < 0.01$) were significant prognostic factors in patients with stage II–III NSCLCs (Table 4). The proportional hazards assumption was met adequately.

DISCUSSION

Recent studies on molecular biology in human cancers have revealed that many molecules affect various biological behaviours of malignant tumours. For example, the activation of oncogenes or the inactivation of tumour suppressor genes, such as K-ras mutation and p53 mutation, could initially cause malignant progression (Huang et al., 1998). In addition, reduced expressions of metastatic suppressor genes, such as E-cadherin (Sulzer et al., 1998; Liu et al., 2001), MRPI/CD9, and KAI1/CD82 (Adachi et al, 1998), are also associated with nodal metastases and a poor prognosis of patients with stage I NSCLCs. Although there were a few wide CIs for the hazard ratios in Table 4, these results might be partly because of factors like differing follow-up.

These results indicate that these biological markers associated with tumour angiogenesis or metastasis are useful for detecting aggressive tumours with high metastatic potential and a poor prognosis among early-stage tumours. In contrast, the methods of surgical resection among stage I NSCLCs, there was no significant difference in the 5-year survival rates between patients treated with a lobectomy and patients treated with a segmentectomy or a wedge resection (75.3 vs 69.0%, $P = 0.18$). Therefore, postoperative adjuvant chemotherapy might be necessary even in patients with stage I NSCLCs (Arriagada et al., 2004; Kato et al., 2004; Strauss et al., 2004; Winton et al., 2004), when tumours are hypervascular or have reduced expressions of metastatic suppressor genes.

On the other hand, these biological markers, including tumour angiogenesis, VEGF-A, VEGF-C, and E-cadherin expression, did not affect the prognosis of patients with stage II–III NSCLCs in the present study. Reductions of MRPI/CD9 and KAI1/CD82 were also not reported to be correlated with the survival of locally advanced stage patients (Adachi et al., 1998). Thus, tumour angiogenesis and tumour metastatic suppressor genes are not clinical indicators for patients with locally advanced NSCLCs.

We evaluated the tumour proliferation rate using the Ki-67 proliferation index (Scagliotti et al, 1993). Ki-67 antibody recognises the nuclear antigen expressed during G1, S, G2, and M phases of the cell cycle and not during the resting (G0) phase. The present study has demonstrated that the Ki-67 proliferation index is one of the significant prognostic factors in patients with stage II–III NSCLCs. In contrast, the Ki-67 proliferation index was not associated with the prognosis of stage I patients.

Regarding TS, its expression is regulated by a polymorphic tandem repeat sequence in the 5′-terminal regulatory region of TS gene (Horie et al, 1995), and it is also regulated by several oncogenes and tumour suppressor genes, including E2F1, retinoblastoma, and p16INK4 (DeGregori et al, 1995; Omura et al, 2000; Angus et al, 2002). Thymidylate synthase plays a central role in the biosynthesis of thymidylate, an essential precursor for DNA synthesis. Recent studies have revealed that TS exhibits oncogene-like activity. Its expression is associated with tumour cell proliferation (Navalgund et al, 1980), as demonstrated in the
present study. Thymidylate synthase protein also downregulates p53 expression through TS protein–p53 mRNA interaction (Chu et al., 1999). In addition, TS can induce a transformed phenotype in mammalian cells (Rahman et al., 2004). The present study has demonstrated that the intratumoral TS expression is one of significant prognostic factors in patients with stage II–III NSCLCs. Furthermore, the intratumoral TS activity has been reported to be related to 5-FU sensitivity (Beck et al., 1994). Several clinical
studies have demonstrated that long-term oral UFT is effective postoperative adjuvant chemotherapy for NSCLC, especially in terms of patient quality of life (Wada et al, 1996; Kato et al, 2004). Many clinical studies on human cancers, including NSCLCs and gastrointestinal tumours, have shown that high TS expression is associated with 5-FU resistance and a poor outcome (Johnston et al, 1995; Yeh et al, 1998; Huang et al, 2000). In the present study, the 5-year survival rate of UFT-treated patients with TS-negative tumours was 53.8%, even in stage II – III, which was significantly higher than those of any other group (7.1 – 15.2%). A recent study has demonstrated that adjuvant chemotherapy with UFT improves the survival among patients with stage I adenocarcinoma of the lung (Kato et al, 2004). In the present study, however, there was no difference in the 5-year survival rates according to the intratumor- al TS status and UFT-based chemotherapy among stage I NSCLCs or among stage I adenocarcinomas. These results might be partly due to the small number of patients studied.

These results suggest that the tumour proliferation rate and TS status are useful markers for identifying less aggressive tumours in locally advanced NSCLCs, and that TS expression is also a useful marker to evaluate responsiveness of UFT-based chemotherapy for these tumours. To our knowledge, there were few clinical reports to identify biological markers useful for the treatment of patients with locally advanced NSCLCs.

ACKNOWLEDGEMENTS

We thank Dr Masakazu Fukushima (Taicho Pharmaceutical Co., Tokyo, Japan) for his kind gift of a rabbit polyclonal antibody for TS.

REFERENCES

Adachi M, Taki T, Konishi T, Huang C, Higashiyama M, Miyake M (1998) Novel staging protocol for non-small-cell lung cancers according to MRP-1/CD9 and KA11/CD82 gene expression. J Clin Oncol 16: 1397 – 1406

Angus SP, Wheeler LJ, Ranmal SA, Zhang X, Markey MP, Mathews CK, Knudsen ES (2002) Retinoblastoma tumour suppressor targets DNTP metabolism to regulate DNA replication. J Biol Chem 277: 44576 – 44584

Arina Y, Koguchi T, Takeno S, Chuo M, Miura T, Uchida Y (2003) Clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in patients with nonsmall cell lung carcinoma. Cancer 97: 457 – 464

Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J, International adjuvant lung cancer trial collaborative group (2004) Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. N Engl J Med 350: 351 – 360

Beck A, Ettiene MC, Cheradame S, Fischel JL, Formento P, Renee N, Milano G (1994) A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil. Eur J Cancer 30A: 1517 – 1522

Cersosimo RJ (2002) Lung cancer: a review. Am J Health-Syst Pharm 59: 611 – 642

Chu E, Copor SM, Ju J, Chen T, Khleif S, Voeller DM, Mizunuma N, Patel M, Maley GF, Maley F, Allegro CJ (1999) Thymidylate synthase protein and p53 mRNA form an in vivo ribonucleoprotein complex. Mol Cell Biol 19: 1582 – 1594

Cox DR (1972) Regression models and life-tables. J R Stat Soc Ser B 34: 187 – 202

DeGregori J, Kowalik T, Nevin JS (1995) Cellular targets for activation by the E2F1 transcriptional factor include DNA synthesis- and G1/S-regulatory genes. Mol Cell Biol 15: 4215 – 4224

Dingemans AC, Witlox MA, Stallaert RA, van der Valk P, Postmus PE, Giaccone G (1999) Expression of DNA topoisomerase IIa and topoisomerase IIb genes predicts survival and response to chemotherapy in patients with small cell lung cancer. Clin Cancer Res 5: 2048 – 2058

Dvorak HF, Brown LF, Detmar M, Dvorak AM (1995) Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146: 1029 – 1039

Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 27 – 31

Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H (1984) Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133: 1710 – 1715

These findings indicate that evaluations of these markers, including the tumour proliferation index and target molecules for chemotherapy, would improve the clinical outcome of patients with locally advanced NSCLCs. Other than TS for UFT, epithelial growth factor receptor for Gefitinib (Mendelsohn and Baselga, 2003) and topoisomerase II for etoposide (Dingemans et al, 1999) might be useful target markers for chemotherapy in advanced NSCLC patients. In addition, such targeted therapies may lead to the development of made-to-order medicine, a new therapeutic strategy for cancer (Rosell et al, 2003; Vokes and Choy, 2003). Regarding target therapies, the present study was a retrospective clinical study with some limitations in its analysis. A further prospective randomised clinical study based on an evaluation of such biological markers, as the NCIC BR.19 study on adjuvant Gefitinib therapy (National Cancer Institute Central IRB protocol, 2002), should be performed.
Masuya D, Huang C, Liu D, Kameyama K, Hayashi E, Yamauchi A, Kobayashi S, Haba R, Yokomise H (2001) The intratumoral expression of vascular endothelial growth factor and interleukin-8 associated with angiogenesis in nonsmall cell lung carcinoma patients. Cancer 92: 2628–2638

Matsuyama K, Chiba Y, Sasaki M, Tanaka H, Muraoka R, Tanigawa N (1998) Tumor angiogenesis as a prognostic marker in operable nonsmall cell lung cancer. Ann Thorac Surg 65: 1405–1409

Mbalaviele G, Dunstan CR, Sasaki A, Williams PJ, Mundy GR, Yoneda T (1996) E-cadherin expression in human breast cancer cells suppresses the development of osteolytic bone metastases in an experimental metastasis model. Cancer Res 56: 4063–4070

McCarty Jr KS, Szabo E, Flowers JL, Cox EB, Leight GS, Miller L, Konrath J, Soper JT, Budwit DA, Creasman WT, Seigler HF, McCarty Sr KS (1986) Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors. Cancer Res 46: 4244s–4248s

Mendelsohn J, Baselga J (2003) Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 21: 2787–2799

Mountain CF (1997) Revisions in the international system for staging lung cancer. Chest 111: 1710–1717

Nakashima T, Huang C, Liu D, Kameyama K, Masuya D, Ueno M, Haba R, Yokomise H (2004) Expression of vascular endothelial growth factor-A and vascular endothelial growth factor-C as prognostic factors for nonsmall cell lung cancer. Med Sci Monit 10: 157–165

National Cancer Institute Central IRB protocol (2002) NCIC BR.19. A phase III prospective randomized, double-blind, placebo-controlled trial of the epidermal growth factor receptor antagonist, ZD1839 (Iressa) in completely resected primary stage IB, II and IIIA non-small cell lung cancer. http://www.ncicirb.org/CIRB_Protocols.asp

Navalgund LG, Rossana C, Muench AJ, Johnson LF (1980) Cell cycle regulation of thymidylate synthetase gene expression in cultured mouse fibroblasts. J Biol Chem 255: 7386–7390

Omura K, Uno Y, Kawakami K, Kanehira E, Tawaraya K, Tsukayama M, Hiranuma C, Watanabe Y (2000) Expression of thymidylate synthase in human gastric and colorectal adenocarcinomas is upregulated by p16/INK4. Hepatogastroenterology 47: 742–745

Rahman L, Voeller D, Rahman M, Lipkowitz S, Allegret C, Barrett JC, Kaye FJ, Zajac-Kaye M (2004) Thymidylate synthase as an oncogene: a novel role for an essential DNA synthesis enzyme. Cancer Cell 5: 341–351

Rosell R, Taron M, Alberola V, Massuti B, Felip E (2003) Genetic testing for chemotherapy in non-small cell lung cancer. Lung Cancer 41: 597–510

Scaglioni GV, Micela M, Gubetta L, Leonardo E, Cappia S, Borasio P, Pozzi E (1993) Prognostic significance of Ki67 labelling in resected non small cell lung cancer. Eur J Cancer 29A: 363–365

Skobe M, Hawighorst T, Jackson DG, Prevo R, Janes L, Velasco P, Riccardi L, Alitalo K, Claffey K, Detmar M (2001) Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 7: 192–198

Strauss GM, Herndon J, Maddaus MA, Johnstone DW, Johnson EA, Watson DM, Sugarbaker DJ, Schilsky RL, Green MR (2004) Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non small cell lung cancer (NSCLC): report of cancer and leukemia group B (CALGB) protocol 9633. Proc Am Soc Clin Oncol 22: 621 (abstract 7019)

Suulzer MA, Leers MP, van Noord JA, Bollen EC, Theunissen PH (1998) Reduced E-cadherin expression is associated with increased lymph node metastasis and unfavorable prognosis in non-small cell lung cancer. Am J Respir Crit Care Med 157: 1319–1323

Wokes EE, Choy H (2003) Targeted therapies for stage III non-small cell lung cancer: integration in the combined modality setting. Lung Cancer 41: S115–S121

Wada H, Hitomi S, Teramatsu T (1996) Adjuvant chemotherapy after complete resection in non-small-cell lung cancer. J Clin Oncol 14: 1048–1054

Winton TL, Livingston R, Johnson D, Rigas J, Cormier Y, Butts C, Ding K, Seymour L, Magoski N, Shepherd F (2004) A prospective randomised trial of adjuvant vinorelbine (VIN) and cisplatin (CIS) in completely resected stage IB and II non small cell lung cancer (NSCLC) Intergroup JBR. 10. Proc Am Soc Clin Oncol 22: 621 (abstract 7018)

Yeh K, Shun C, Chen C, Lin J, Lee W, Lee P, Chen Y, Cheng A (1998) High expression of thymidylate synthase is associated with the drug resistance of gastric carcinoma to high dose 5-fluorouracil-based systemic chemotherapy. Cancer 82: 1626–1631